01/22/2021 at 12:00 pm
Psoriatic arthritis (PsA) can have serious debilitating effects on peripheral joints, the spine, tendon insertions, and fingers. Management of PsA has improved with therapies such as nonpharmacologic and symptomatic treatments, oral small molecules, tumor necrosis factor inhibitors, interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, CTLA4-lg, Janus kinase (JAK)/TyK2 inhibitors, and IL-23 inhibitors; however, complete disease control has not yet been achieved.
This CME Outfitters Snack focuses on evaluating the mechanistic rationale for novel and emerging treatments for PsA as well as assessing safety and efficacy data for current and emerging JAK inhibitors to determine their role in the management of PsA in order to help narrow the treatment gap.
At the end of this CME/CE activity, participants should be able to assess the mechanistic rationale for novel and emerging treatments for psoriatic arthritis, including key clinical efficacy and safety data for targeted treatments.
Supported by an educational grant from Bristol Myers Squibb Company.
Physicians, PAs, nurse practitioners, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Fernandez reports that he receives grants from Mallinckrodt and Novartis. He receives research support from AbbVie Inc.; Corbus Pharmaceuticals Holdings, Inc.; Mallinckrodt Pharmaceuticals; and Pfizer Inc. He is on the speakers bureau for AbbVie Inc.; Mallinckrodt Pharmaceuticals; and Novartis. He is a consultant for AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Mallinckrodt Pharmaceuticals; and Novartis.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-030-H01-P
Call us at (877) CME-PROS or (877) 263-7767.